OBJECTIVE： To systematically review the efficacy and safety of edaravone combined with clopidogrel versus clopidogrel alone in the treatment of acute cerebral infarction， and provide evidence-based reference for clinic. METHODS： Retrieved from PubMed， Medline （Ovid）， CJFD， VIP Database and Wanfang Database， according to inclusion and exclusion criteria， retrieval strategy was developed， and randomized controlled trials （RCT） about edaravone combined with clopidogrel versus clopidogrel alone in the treatment of acute cerebral infarction were collected. Meta-analysis was performed by using Rev Man 5.3 software after quality evaluation and data extraction. RESULTS： Totally 18 RCTs were enrolled， involving 1 611 patients. Results of Meta-analysis showed， the total effective rate [OR＝4.07，95％CI（3.01，5.49），P＜0.001]， basic recovery rate [OR＝2.09，95％CI （1.68，2.59），P＜0.001]， and ADL score of daily living ability [MD＝13.42，95％CI（11.62，15.23），P＜0.001] were higher than control group，while neurological deficit NIHSS score was lower than control group[MD＝－6.20，95％CI（－8.14，－4.26），P＜0.001] with statistic significances； there were no significant differences in late recurrence rate [OR＝0.52，95％CI（0.24，1.13），P＝0.10] and the incidence of adverse reactions in 2 groups. CONCLUSIONS： Edaravone combined with clopidogrel shows better efficacy than clopidogrel alone in the treatment of acute cerebral infarction， can correct neuroloyic impairment and improve the activity of daily living. The safety of them are similar to each other.